Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes.
J Am Coll Cardiol
; 32(7): 1996-2002, 1998 Dec.
Article
em En
| MEDLINE
| ID: mdl-9857884
ABSTRACT
OBJECTIVES:
The purpose of this study was to compare the outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI) when performed with or without the platelet glycoprotein IIb/IIIa antibody, abciximab.BACKGROUND:
Abciximab improves the outcome of angioplasty but the effect of abciximab in primary angioplasty has not been investigated.METHODS:
Data were collected from a computerized database. Follow-up was by telephone or review of outpatient or hospital readmission records.RESULTS:
A total of 182 consecutive patients were included; 103 received abciximab and 79 did not. The procedural success rate was 95% in the two groups. At 30-day follow-up, the composite event rate of unstable angina, reinfarction, target vessel revascularization and death from all causes was 13.5% in the group of patients who did not receive abciximab, 4% (p < 0.05) in the abciximab group and 2.4% (p < 0.05) in the subgroup of patients (n = 87) who completed the 12-h abciximab infusion. At the end of follow-up (mean 7+/-4 months), the composite event rate was 32.4%, 17% (p < 0.05) and 13.1% (p < 0.01) in these three categories respectively. Abciximab bolus followed by a 12-h infusion was an independent predictor of event-free survival, in a Cox proportional hazards model (relative risk 0.49; 95% confidence interval 0.24 to 0.99; p < 0.05).CONCLUSIONS:
Abciximab given at the time of primary angioplasty may improve the short- and medium-term outcome of patients with acute MI, especially when a 12-h infusion is completed.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fragmentos Fab das Imunoglobulinas
/
Inibidores da Agregação Plaquetária
/
Angioplastia Coronária com Balão
/
Anticorpos Monoclonais
/
Infarto do Miocárdio
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Coll Cardiol
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos